Payment received

RNS Number : 9314R

Omega Diagnostics Group PLC

11 July 2022

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Payment received

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that it has received payment from Abingdon Health plc ("Abingdon") in relation to the manufacture and supply of AbC-19™ Rapid tests, a COVID-19 lateral flow antibody test.

The payment was due under the Supply of Goods contract announced on 19 October 2020, and was made following confirmation from Abingdon that a cash payment had been received from the Department for Health & Social Care ("DHSC") on 7 July 2022, as part of a settlement agreement relating to outstanding invoices due from DHSC to Abingdon.

Contacts: 

Omega Diagnostics Group PLC		www.omegadx.com
Jag Grewal, Chief Executive Officer		via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd		Tel: [phone]
Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)
Alice Lane/ Harriet Ward (ECM)
Walbrook PR Limited	Tel: [phone] or [e-mail]
Paul McManus		Mob: [phone]
Lianne Applegarth		Mob: [phone]
Sam Allen		Mob: [phone]

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

END

 

 

MSCDDGDRXDBDGDG